Research ArticleAccepted Articles
Open Access
Treatment response to tumor necrosis factor inhibitors and methotrexate monotherapy in adults with juvenile idiopathic arthritis: Data from NORDMARD
Imane Bardan, Karen Minde Fagerli, Joe Sexton, Tore K. Kvien, Gunnstein Bakland, Pawel Mielnik, Yi Hu, Gunhild Lien, Berit Flatø, Øyvind Molberg, Eirik Klami Kristianslund and Anna-Birgitte Aga
The Journal of Rheumatology November 2022, jrheum.220645; DOI: https://doi.org/10.3899/jrheum.220645
Imane Bardan
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Karen Minde Fagerli
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Joe Sexton
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Tore K. Kvien
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Gunnstein Bakland
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Pawel Mielnik
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Yi Hu
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Gunhild Lien
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Berit Flatø
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Øyvind Molberg
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Eirik Klami Kristianslund
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Anna-Birgitte Aga
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Treatment response to tumor necrosis factor inhibitors and methotrexate monotherapy in adults with juvenile idiopathic arthritis: Data from NORDMARD
Imane Bardan, Karen Minde Fagerli, Joe Sexton, Tore K. Kvien, Gunnstein Bakland, Pawel Mielnik, Yi Hu, Gunhild Lien, Berit Flatø, Øyvind Molberg, Eirik Klami Kristianslund, Anna-Birgitte Aga
The Journal of Rheumatology Nov 2022, jrheum.220645; DOI: 10.3899/jrheum.220645
Accepted manuscript
Treatment response to tumor necrosis factor inhibitors and methotrexate monotherapy in adults with juvenile idiopathic arthritis: Data from NORDMARD
Imane Bardan, Karen Minde Fagerli, Joe Sexton, Tore K. Kvien, Gunnstein Bakland, Pawel Mielnik, Yi Hu, Gunhild Lien, Berit Flatø, Øyvind Molberg, Eirik Klami Kristianslund, Anna-Birgitte Aga
The Journal of Rheumatology Nov 2022, jrheum.220645; DOI: 10.3899/jrheum.220645